CN106974950A - Application of the Ligusticum wallichii essential oil in treatment medicine for treating rheumatoid arthritis and Saving cortilage health products are prepared - Google Patents
Application of the Ligusticum wallichii essential oil in treatment medicine for treating rheumatoid arthritis and Saving cortilage health products are prepared Download PDFInfo
- Publication number
- CN106974950A CN106974950A CN201710258327.2A CN201710258327A CN106974950A CN 106974950 A CN106974950 A CN 106974950A CN 201710258327 A CN201710258327 A CN 201710258327A CN 106974950 A CN106974950 A CN 106974950A
- Authority
- CN
- China
- Prior art keywords
- ligusticum wallichii
- essential oil
- wallichii essential
- oil
- rheumatoid arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000112528 Ligusticum striatum Species 0.000 title claims abstract description 223
- 239000000341 volatile oil Substances 0.000 title claims abstract description 178
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 51
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 230000036541 health Effects 0.000 title claims abstract description 8
- ZPIKVDODKLJKIN-NSHDSACASA-N Senkyunolide Chemical compound C1CC=CC2=C1[C@H](CCCC)OC2=O ZPIKVDODKLJKIN-NSHDSACASA-N 0.000 claims description 66
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 claims description 35
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 239000003921 oil Substances 0.000 claims description 23
- 235000019476 oil-water mixture Nutrition 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 15
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- 238000004821 distillation Methods 0.000 claims description 8
- 201000004595 synovitis Diseases 0.000 claims description 8
- 230000008961 swelling Effects 0.000 claims description 6
- 239000012530 fluid Substances 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 14
- 208000002193 Pain Diseases 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 description 24
- MJPMPMZXJIZPRE-UHFFFAOYSA-N 3-butyl-5,6,7,7a-tetrahydro-3h-2-benzofuran-1-one Chemical compound C1CCC=C2C(CCCC)OC(=O)C21 MJPMPMZXJIZPRE-UHFFFAOYSA-N 0.000 description 22
- 230000001225 therapeutic effect Effects 0.000 description 21
- 150000002148 esters Chemical class 0.000 description 17
- 239000007788 liquid Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 238000004062 sedimentation Methods 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 108010074051 C-Reactive Protein Proteins 0.000 description 9
- 102100032752 C-reactive protein Human genes 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000011149 active material Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 4
- 239000004519 grease Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241000244355 Ligusticum Species 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 229930183325 senkyunolide Natural products 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 244000061520 Angelica archangelica Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000004406 stave cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides Ligusticum wallichii essential oil pharmaceutical field new application.Specially application of the Ligusticum wallichii essential oil in treatment medicine for treating rheumatoid arthritis and Saving cortilage health products are prepared.Ligusticum wallichii essential oil can effectively improve the related physicochemical property of joint fluid and blood, improve the symptoms such as distending pain, deformity, the inflammation of patient.Ligusticum wallichii essential oil can effectively treat rheumatoid arthritis, also can as Saving cortilage health products.Ligusticum wallichii essential oil is prepared and easy to use, is easy to patient to use, toxic side effect is low.
Description
Technical field
The present invention relates to pharmaceutical field, more particularly to a kind of Ligusticum wallichii essential oil prepare treatment medicine for treating rheumatoid arthritis with
And the application in Saving cortilage health products.
Background technology
Rheumatoid arthritis (RA) is a kind of unknown systemic disease chronic, based on inflammatory synovitis of cause of disease.
It is characterized in that hand, the multi-joint of sufficient Minor articulus, symmetry, aggressive arthritis, are often accompanied by organ outside joint and are involved blood
Clear rheumatoid factor positive, can cause joint deformity and function to be lost.RA morbidity may be with heredity, infection, sex hormone etc.
It is relevant.The arthritic pathology of RA mainly has synovial membrane stave cell hyperplasia, an interstitial massive inflammatory cells infiltrated, and capilary is new
The raw, formation of pannus and the destruction of cartilage and bone tissue etc..This disease is more common in elderly population, is apt to occur in women.Clinical manifestation
It is morning stiffness, multi-joint by weight, joint deformity etc..
Existing treatment rheumatoid arthritis mainly by operation, acupuncture, the smoked mode such as end, but be due to these methods all
Professional person is needed to be operated, patient is only capable of going to hospital to be seen a doctor, it is impossible to carry out autonomous treatment at home, meanwhile,
The financial cost of the costly treatment for adding patient of traditional treatment method.
The content of the invention
Treatment rheumatoid joint is being prepared it is an object of the invention to provide the new application of Ligusticum wallichii essential oil, i.e. Ligusticum wallichii essential oil
Application and Ligusticum wallichii essential oil in scorching medicine prepare the application in Saving cortilage health products.
Rheumatoid arthritis of the present invention includes synovitis, joint deformity and painful swelling of joints.
Wherein, Ligusticum wallichii essential oil includes 10%-70% Ligustilide by mass percentage.Preferably, by quality percentage
Also include 8%-10% parts of Senkyunolide As, 9%-13% parts of neocindilides than meter Ligusticum wallichii essential oil.
The method for preparing Ligusticum wallichii essential oil be after Ligusticum wallichii is crushed according to mass ratio be 1：0.3-1.2 ratio and deionized water
Mixing, and soak 7-24 hours.The Ligusticum wallichii of moistening is heated using water vapour, mixed vapour is obtained.Condense mixed vapour
Oil water mixture is obtained, carrying out water-oil separating to oil water mixture obtains Ligusticum wallichii essential oil.Particle diameter after wherein Ligusticum wallichii is crushed is 4-
7mm。
Prepare Ligusticum wallichii essential oil method can also be Ligusticum wallichii is crushed after according to mass ratio be 1：2-15 ratio is mixed with water
Merging boils distillation and obtains mixed vapour.Water-oil separating, which is carried out, after condensation mixed vapour obtains Ligusticum wallichii essential oil.
There is good effect for treatment rheumatoid arthritis by clinical trial Ligusticum wallichii essential oil.By clinically right
The detection of joint fluid finds that Ligusticum wallichii essential oil can effectively improve the physicochemical property of joint fluid so that the physicochemical property of joint fluid is just
Often, and then show that it has obvious curative effect.Meanwhile, by rheumatoid factor, C reactive protein, erythrocyte sedimentation in blood
Rate etc. is tested and analyzed, it is found that the numerical value of above-mentioned blood testing project returns to normal range (NR) using after Ligusticum wallichii essential oil
In value, show that Ligusticum wallichii essential oil has good therapeutic effect for rheumatoid arthritis.
It can thus be appreciated that beneficial effects of the present invention are：
Application of the present invention to Ligusticum wallichii essential oil is excavated, and has opened up Ligusticum wallichii essential oil in treatment medicine for treating rheumatoid arthritis
In new application, it has good therapeutic effect for rheumatoid arthritis.For being closed caused by rheumatoid arthritis
The symptoms such as section distending pain, joint deformity, synovitis also have good therapeutic effect.
Embodiment
, below will be in the embodiment of the present invention to make the purpose, technical scheme and advantage of the embodiment of the present invention clearer
Technical scheme be clearly and completely described.Unreceipted actual conditions person, builds according to normal condition or manufacturer in embodiment
The condition of view is carried out.Agents useful for same or the unreceipted production firm person of instrument, are the conventional production that can be obtained by commercially available purchase
Product.
Ligusticum wallichii essential oil is the total volatile oil extracted from chuanxiong, and it can be applied to treat medicine for treating rheumatoid arthritis
In, it further can be applied to treatment synovitis, joint deformity and painful swelling of joints.Further Ligusticum wallichii essential oil includes 10%-
70% Ligustilide.Preferably, Ligusticum wallichii essential oil also includes 8%-10% parts of Senkyunolide As, 9%- by mass percentage
13% part of neocindilide.
The not only a certain single material of drug effect is played in Ligusticum wallichii essential oil, but Ligustilide and Ligusticum wallichii essential oil are being carried
The common performance drug effect of other esters interaction produced during taking.And in Ligusticum wallichii essential oil in the Jehol Ligusticum Rhizome containing said ratio
It is more preferable to treating the drug effect of rheumatoid arthritis when ester, Senkyunolide A, neocindilide, while the proportioning ensures three
Between can play synergy, the synergy reaches preferably effect.Through repeatedly research is found repeatedly, if in Ligusticum wallichii essential oil
Ligustilide content is too low, and the effect of the too high levels of other esters then Ligusticum wallichii essential oil treatment rheumatoid arthritis drastically declines
Even disappear, Senkyunolide A, neocindilide three proportion relation do not apply in medicine treat within the above range, then
Effect is slightly poor.
Ligustilide, alias ligustilide is the main work of China's traditional Chinese medicine umbelliferae angelica volatile oil
Property composition, it has very strong spasmolysis, relievings asthma, sedation, can improve microcirculation, relaxing smooth muscle, antibacterial, improve immunity of organism
Regulatory function, has good when it is mixed with the esters of other in Rhizoma Chuanxiong extract applied in medicine to treatment rheumatoid arthritis
Good curative effect.Ligustilide is found to be mixed medicament for treating class with Senkyunolide A and neocindilide mating reaction
Effect is more preferable during rheumatic arthritis.
Preparing the method for the Ligusticum wallichii essential oil for the treatment of rheumatoid arthritis is：
S1, the Ligusticum wallichii being commercially available carries out to mechanical crushing, the size controlling of the Ligusticum wallichii after crushing is in 2-5mm, preferably
The particle diameter of Ligusticum wallichii is 3mm.
Ligusticum wallichii, which crush, is easy to the follow-up material for needing to extract easily to dissolve or be evaporated, while increasing river
The contact area of rhizome of chuanxiong and solvent, reduces the usage amount of solvent, meanwhile, the extraction time of active ingredient is shortened, and then save
Production cost.
S2, by the Ligusticum wallichii of crushing according to mass ratio be 1：0.3-1.2 ratio mixes with deionized water and soaks Ligusticum wallichii 7-
24 hours.
Using the deionized water of this ratio, Ligusticum wallichii complete wetting can make it that, but the active material in Ligusticum wallichii will not be caused
It is dissolved, is easy to follow-up operation.Meanwhile, if wetting is insufficient, when subsequently directly being extracted using vapor, it is impossible to completely
Active material in Ligusticum wallichii is extracted, extraction efficiency is reduced.
S3, using vapor the Ligusticum wallichii of moistening is heated, obtain mixed vapour, condensation mixed vapour obtains profit and mixed
Compound, carries out water-oil separating to oil water mixture and obtains Ligusticum wallichii essential oil.
Vapor has higher energy, and heat exchange is carried out to the water on Ligusticum wallichii surface when it is by moistening Ligusticum wallichii,
So that water has higher energy, then the active material in Ligusticum wallichii is dissolved out, vapor continues to carry out heat exchange with water,
So that the energy of water is further lifted, and then it is steam to gasify, meanwhile, the active material being dissolved in water, also being gasified is
Gas, as vapor together leaves Ligusticum wallichii, and then reaches the effect of extraction.And when using vapor, vapor energy is high, make
Obtain active material dissolution efficiency high.Vapor is condensed into aqueous water after carrying out heat exchange with water, is attached to Ligusticum wallichii surface, further
Active material in ground dissolving Ligusticum wallichii, the vapor being then passed through carries out heat exchange with water, water is changed into vapor, river is taken away again
Rhizome of chuanxiong.Whole process keeps the circulation of dissolving-evaporation-condensation-dissolving, it is ensured that the effect of extraction, improves extraction efficiency, simultaneously
The waste of raw material is reduced, production cost has been saved.The temperature of the vapor used is 150-200 DEG C.
Obtained mixed vapour is condensed at room temperature.Most of activity obtained out of Ligusticum wallichii is ethereal oil, its
It is water insoluble, there is the line of demarcation of distinctness between water.Using simple Liquid liquid Separation equipment, such as separatory funnel.
The method for preparing the Ligusticum wallichii essential oil for the treatment of rheumatoid arthritis can also be：
After Ligusticum wallichii is crushed according to mass ratio be 1：2-15 ratio, which mixes with water and boils distillation, obtains mixed vapour.It is cold
Water-oil separating, which is carried out, after solidifying mixed vapour obtains Ligusticum wallichii essential oil.
The particle size range of Ligusticum wallichii after crushing is 2-5mm, it is therefore preferable to 3mm.Due to the method, to use Ligusticum wallichii direct
Boil and extracted with water Hybrid Heating, in order to ensure extraction effect, it is necessary to increase using water.Meanwhile, after boiling, in Ligusticum wallichii
Active material dissolution rate and quantity increase, improve extraction efficiency.Boil so that water is changed into vapor, drive volatilization
Property material outflow, and then complete extract.Then vapor and volatile oil are carried out condensing the water and fluid that obtain liquid,
Water oil is immiscible, carries out Liquid liquid Separation and obtains Ligusticum wallichii essential oil, for example, is directly separated using separatory funnel.
Activity substance content is higher in the Ligusticum wallichii essential oil prepared, when directly being acted on human body, site of action meeting
There are the phenomenons such as violent pain, redness, it is impossible to play therapeutic effect, may further aggravate the pain of patient, increase
The incidence of disease of patient.In order to ensure therapeutic effect, slow down the side effect after patient's use, typically by Ligusticum wallichii essential oil and fat oil,
The greases such as maize germ oil, rapeseed oil, soybean oil be mixed with obtaining finish.The ratio of the grease used is Ligusticum wallichii essential oil
The 3-10% of usage amount.
Generally using each composition of Ligusticum wallichii essential oil made from the above method includes mass percentage content for 10%-70%'s
Ligustilide, remaining esters include Senkyunolide A and neocindilide etc..
Embodiment 1
Initial Ligusticum wallichii essential oil is made by following steps：1Kg Ligusticum wallichiis are crushed, particle diameter be 5 millimeters, then gone with 1Kg from
Sub- water mixing, moistening 1Kg Ligusticum wallichiis 13 hours.150 DEG C of vapor is constantly slow transitted through to the Ligusticum wallichii of moistening, then condensation passes through
The mixed vapour of Ligusticum wallichii is moistened, oil water mixture is obtained, carrying out water-oil separating using separatory funnel obtains Ligusticum wallichii essential oil.Due to logical
The Ligusticum wallichii essential oil of aforesaid way extraction is crossed, its contained each composition can not possibly be with being precisely worth unanimously, therefore in embodiment needed for experimenter
The middle Ligusticum wallichii essential oil adjusted using pure Ligustilide, pure Senkyunolide A and dew cnidiumlactone after extracting, the river after regulation
Rhizome of chuanxiong essential oil includes 10% Ligustilide, 6% Senkyunolide A and 13% neocindilide, and remaining component is remaining esters.
Embodiment 2
Initial Ligusticum wallichii essential oil is made by following steps：0.9Kg Ligusticum wallichiis are crushed, particle diameter is 6 millimeters, then with 0.45Kg
Deionized water is mixed, moistening 0.9Kg Ligusticum wallichiis 7 hours.170 DEG C of vapor is constantly slow transitted through to the Ligusticum wallichii of moistening, it is then cold
The mixed vapour by moistening Ligusticum wallichii is coagulated, oil water mixture is obtained, carrying out water-oil separating using separatory funnel obtains Ligusticum wallichii essential oil.
Due to the Ligusticum wallichii essential oil extracted through the above way, its contained each composition can not possibly be consistent with accurate value needed for experimenter, therefore
The Ligusticum wallichii essential oil after extracting, regulation are adjusted in embodiment using pure Ligustilide, pure Senkyunolide A and dew cnidiumlactone
Ligusticum wallichii essential oil afterwards includes 15% Ligustilide, 7% Senkyunolide A and 12% neocindilide, and remaining component is remaining ester
Class.
Embodiment 3
Initial Ligusticum wallichii essential oil is made by following steps：1.1Kg Ligusticum wallichiis are crushed, particle diameter is 7 millimeters, then with 0.33Kg
Deionized water is mixed, moistening 1.1Kg Ligusticum wallichiis 20 hours.200 DEG C of vapor is constantly slow transitted through to the Ligusticum wallichii of moistening, it is then cold
The mixed vapour by moistening Ligusticum wallichii is coagulated, oil water mixture is obtained, carrying out water-oil separating using separatory funnel obtains Ligusticum wallichii essential oil.
Due to the Ligusticum wallichii essential oil extracted through the above way, its contained each composition can not possibly be consistent with accurate value needed for experimenter, therefore
The Ligusticum wallichii essential oil after extracting, regulation are adjusted in embodiment using pure Ligustilide, pure Senkyunolide A and dew cnidiumlactone
Ligusticum wallichii essential oil afterwards includes 20% Ligustilide, 8% Senkyunolide A and 11% neocindilide, and remaining component is remaining ester
Class.
Embodiment 4
Initial Ligusticum wallichii essential oil is made by following steps：1.2Kg Ligusticum wallichiis are crushed, particle diameter is 4 millimeters, then with 1.44Kg
Deionized water is mixed, moistening 1.2Kg Ligusticum wallichiis 24 hours.170 DEG C of vapor is constantly slow transitted through to the Ligusticum wallichii of moistening, it is then cold
The mixed vapour by moistening Ligusticum wallichii is coagulated, oil water mixture is obtained, carrying out water-oil separating using separatory funnel obtains Ligusticum wallichii essential oil.
Due to the Ligusticum wallichii essential oil extracted through the above way, its contained each composition can not possibly be consistent with accurate value needed for experimenter, therefore
The Ligusticum wallichii essential oil after extracting, regulation are adjusted in embodiment using pure Ligustilide, pure Senkyunolide A and dew cnidiumlactone
Ligusticum wallichii essential oil afterwards includes 30% Ligustilide, 13% Senkyunolide A and 10% neocindilide, and remaining component is remaining ester
Class.
Embodiment 5
Initial Ligusticum wallichii essential oil is made by following steps：0.94Kg Ligusticum wallichiis are crushed, particle diameter be 5 millimeters, then with
0.75Kg deionized waters are mixed, moistening 0.94Kg Ligusticum wallichiis 16 hours.180 DEG C of vapor is constantly slow transitted through to the river of moistening
Rhizome of chuanxiong, then condenses the mixed vapour by moistening Ligusticum wallichii, obtains oil water mixture, and carrying out water-oil separating using separatory funnel obtains
Ligusticum wallichii essential oil.Due to the Ligusticum wallichii essential oil extracted through the above way, its contained each composition can not possibly be with being precisely worth needed for experimenter
Unanimously, therefore in embodiment the Ligusticum wallichii after extracting is adjusted using pure Ligustilide, pure Senkyunolide A and dew cnidiumlactone
Essential oil, the Ligusticum wallichii essential oil after regulation includes 40% Ligustilide, 10% Senkyunolide A and 9% neocindilide, remaining component
For remaining esters.
Embodiment 6
Initial Ligusticum wallichii essential oil is made by following steps：0.98Kg Ligusticum wallichiis are crushed, particle diameter be 6 millimeters, then with
0.79Kg deionized waters are mixed, moistening 0.98Kg Ligusticum wallichiis 10 hours.160 DEG C of vapor is constantly slow transitted through to the river of moistening
Rhizome of chuanxiong, then condenses the mixed vapour by moistening Ligusticum wallichii, obtains oil water mixture, and carrying out water-oil separating using separatory funnel obtains
Ligusticum wallichii essential oil.Due to the Ligusticum wallichii essential oil extracted through the above way, its contained each composition can not possibly be with being precisely worth needed for experimenter
Unanimously, therefore in embodiment the Ligusticum wallichii after extracting is adjusted using pure Ligustilide, pure Senkyunolide A and dew cnidiumlactone
Essential oil, the Ligusticum wallichii essential oil after regulation includes 50% Ligustilide, 6% Senkyunolide A and 8% neocindilide, remaining component
For remaining esters.
Embodiment 7
Initial Ligusticum wallichii essential oil is made by following steps：1.1Kg Ligusticum wallichiis are crushed, particle diameter is 5 millimeters, then with 2.2Kg
Deionized water, which mixes and boils distillation, obtains mixed vapour, then condenses mixed vapour, obtains oil water mixture, using a point liquid leakage
Bucket carries out water-oil separating and obtains Ligusticum wallichii essential oil.Due to the Ligusticum wallichii essential oil extracted through the above way, its contained each composition is impossible
It is consistent with being precisely worth needed for experimenter, therefore pure Ligustilide, pure Senkyunolide A and dew cnidiumlactone are used in embodiment
To adjust the Ligusticum wallichii essential oil after extracting, it is new that the Ligusticum wallichii essential oil after regulation includes 60% Ligustilide, 8% Senkyunolide A and 7%
Cnidiumlactone, remaining component is remaining esters.
Embodiment 8
Initial Ligusticum wallichii essential oil is made by following steps：1.3Kg Ligusticum wallichiis are crushed, particle diameter is 7 millimeters, then with 19.5Kg
Deionized water, which mixes and boils distillation, obtains mixed vapour, then condenses mixed vapour, obtains oil water mixture, using a point liquid leakage
Bucket carries out water-oil separating and obtains Ligusticum wallichii essential oil.Due to the Ligusticum wallichii essential oil extracted through the above way, its contained each composition is impossible
It is consistent with being precisely worth needed for experimenter, therefore pure Ligustilide, pure Senkyunolide A and dew cnidiumlactone are used in embodiment
To adjust the Ligusticum wallichii essential oil after extracting, the Ligusticum wallichii essential oil after regulation includes 70% Ligustilide, 15% Senkyunolide A and 15%
Neocindilide, remaining component is remaining esters.
Embodiment 9
Initial Ligusticum wallichii essential oil is made by following steps：1.12Kg Ligusticum wallichiis are crushed, particle diameter be 6 millimeters, then with
8.96Kg deionized waters, which mix and boil distillation, obtains mixed vapour, then condenses mixed vapour, obtains oil water mixture, uses
Separatory funnel carries out water-oil separating and obtains Ligusticum wallichii essential oil.Due to the Ligusticum wallichii essential oil extracted through the above way, its contained each composition
Can not possibly be with being precisely worth unanimously needed for experimenter, therefore pure Ligustilide, pure Senkyunolide A and dew snake are used in embodiment
Bed lactone adjusts the Ligusticum wallichii essential oil after extracting, and Ligusticum wallichii essential oil after regulation includes 10% Ligustilide, 3% Senkyunolide A
With 7% neocindilide, remaining component is remaining esters.
Embodiment 10
Initial Ligusticum wallichii essential oil is made by following steps：1.18Kg Ligusticum wallichiis are crushed, particle diameter be 6 millimeters, then with
11.8Kg deionized waters, which mix and boil distillation, obtains mixed vapour, then condenses mixed vapour, obtains oil water mixture, uses
Separatory funnel carries out water-oil separating and obtains Ligusticum wallichii essential oil.Due to the Ligusticum wallichii essential oil extracted through the above way, its contained each composition
Can not possibly be with being precisely worth unanimously needed for experimenter, therefore pure Ligustilide, pure Senkyunolide A and dew snake are used in embodiment
Bed lactone adjusts the Ligusticum wallichii essential oil after extracting, and Ligusticum wallichii essential oil after regulation includes 50% Ligustilide, 7% Senkyunolide A
With 4% neocindilide, remaining component is remaining esters.
Embodiment 11
Initial Ligusticum wallichii essential oil is made by following steps：1.25Kg Ligusticum wallichiis are crushed, particle diameter is 6 millimeters, then with 7.5Kg
Deionized water, which mixes and boils distillation, obtains mixed vapour, then condenses mixed vapour, obtains oil water mixture, using a point liquid leakage
Bucket carries out water-oil separating and obtains Ligusticum wallichii essential oil.Due to the Ligusticum wallichii essential oil extracted through the above way, its contained each composition is impossible
It is consistent with being precisely worth needed for experimenter, therefore pure Ligustilide, pure Senkyunolide A and dew cnidiumlactone are used in embodiment
To adjust the Ligusticum wallichii essential oil after extracting, it is new that the Ligusticum wallichii essential oil after regulation includes 70% Ligustilide, 5% Senkyunolide A and 4%
Cnidiumlactone, remaining component is remaining esters.
Experimental example
The present invention using with Ligusticum wallichii essential oil as treatment medicine for treating rheumatoid arthritis in terms of pharmacological evaluation and result come
Illustrate its new application in pharmaceutical field.
Human trial 1
Test example is the Ligusticum wallichii essential oil of embodiment 1, and comparative example 1 contains 8% Senkyunolide A and 8% for what is manually allocated
Neocindilide residue component is the essential oil of remaining esters；Comparative example 2 is pure Ligustilide.
Concrete operation method
The illness shown due to the patient with rheumatoid arthrosis mostly and meanwhile have synovitis, joint deformity and
The symptom of painful swelling of joints extracts the age in 30-50 one full year of life, and women, 135 rheumatoid arthritis examples simultaneously have above-mentioned simultaneously
135 patients are divided into 3 groups, one of which uses the essential oil of comparative example 1, one group uses comparative example 2 by the patient of three kinds of symptoms
Ligustilide, last group uses the Ligusticum wallichii essential oil of embodiment 1.Pass through fat oil, maize germ oil, rapeseed oil, soybean oil etc.
In one or more greases carry out mixed diluting, the consumption of dilution finish is the 3-10% of grease or essential oil usage amount, experiment
Example 1, comparative example 1 are identical with the dilution finish and extension rate used in the essential oil of comparative example 2.It is daily 7 points, in 15 points and 23
Three periods of point smear the finish that 1 gram of corresponding above-mentioned grease or essential oil are made in affected areas, and massage 15 minutes, with illness
Region heating slightly is advisable.
Wherein, it is set to what pain, arthroncus, tenderness, deformity, morning stiffness mitigated effectively；By pain, tenderness, stiff, pass
Section swelling, deformity or morning stiffness disappear for more than one, and other limitation of activity mitigate, and are determined as effective；By arthralgia, tenderness,
Morning stiffness, arthroncus, disappear, the mitigation of limitation of activity and joint deformity limitation of activity is judged to recovery from illness.
3 groups of example patients are paid a return visit at 30 days and 60 days respectively and return visit information is filled in.Use the Ligusticum wallichii essence of comparative example 1
The return visit information of oil is shown in Table 1, is shown in Table 2 using the return visit information of the Ligusticum wallichii essential oil of comparative example 2, uses the Ligusticum wallichii essential oil of embodiment 1
Return visit information be shown in Table 3.
The return visit information of the essential oil of the comparative example 1 of table 1
| It is invalid | Effectively | It is effective | Recovery from illness | |
| 30 days | 41 | 4 | 0 | 0 |
| 60 days | 40 | 5 | 0 | 0 |
The return visit information of the grease of the comparative example 2 of table 2
| It is invalid | Effectively | It is effective | Recovery from illness | |
| 30 days | 40 | 5 | 0 | 0 |
| 60 days | 15 | 29 | 1 | 0 |
The return visit information of the Ligusticum wallichii essential oil of the embodiment 1 of table 3
| It is invalid | Effectively | It is effective | Recovery from illness | |
| 30 days | 1 | 32 | 12 | 0 |
| 60 days | 0 | 1 | 14 | 30 |
Clinical Practice is proved：Ligusticum wallichii essential oil system when simultaneously containing Ligustilide, Senkyunolide A and neocindilide
Into finish there is preferable therapeutic effect to rheumatoid arthritis, it is the oil that main component is made that Ligustilide, which is used alone,
Agent can be used in treating rheumatoid arthritis, but its therapeutic effect is general, if being singly Senkyunolide A and neocindilide system
Into finish then almost there is no therapeutic effect to rheumatoid arthritis.
By table 3, the Ligusticum wallichii essential oil of embodiment 1 can be used for the treatment of rheumatoid arthritis, use 30 days
71% effectively is reached, obvious effective rate reaches 31% up to 27% using obvious effective rate after 60 days, and cure rate is 67%.Ligusticum wallichii essential oil
Action principle is：Ligusticum wallichii essential oil can be directly entered joint, tendon and the periosteum for occurring lesion by Transdermal absorption, improve disease
Become the microcirculation at position, prevent the generation of the further lesion of rheumatoid arthritis, and the lesion region having occurred and that is carried out
Repair.
Human trial 2
The blood of the 45 rheumatoid arthritis patients acted on embodiment 1 in human trial 1 is extracted and examined
Survey, detection 3 times is extracted altogether.3 blood extracted are respectively blood before unused Ligusticum wallichii essential oil, using Ligusticum wallichii essential oil 30 days after
Blood, use the blood after Ligusticum wallichii essential oil 60 days.
The project of detection is that content, erythrocyte sedimentation rate (ESR) (erythrocyte sedimentation rate) and the C reactive protein of rheumatoid factor in blood contain
Amount.Wherein, rheumatoid factor is detected that testing result is shown in Table 4 using emulsion condensation experiment；Erythrocyte sedimentation rate passes through Wei Shi natural subsidences
Method, testing result is shown in Table 5；C reactive protein content detects that testing result is shown in Table 6 using Immunity transmission turbidity.
The rheumatoid factor content detection result of table 4
| <20IU/ml | 20-40IU/ml | 40-80IU/ml | >80IU/ml | |
| It is not used | 0 | 3 | 20 | 22 |
| Use 30 days | 10 | 24 | 7 | 4 |
| Use 60 days | 38 | 7 | 0 | 0 |
It is 0-20IU/ml using the normal value of the rheumatoid factor content of emulsion condensation testing inspection, and can by table 4
Know, after Ligusticum wallichii essential oil, the rheumatoid factor content of rheumatoid arthritis patient substantially tails off, and uses class wind after 60 days
The ratio that wet factor content returns to normal value is 84%, and the reduction of rheumatoid factor quantity shows that normal IgG molecules contain in patient's body
Amount increase, and IgG-RF complex contents are reduced, and then joint injury is reduced, while reducing inflammation and lifting the immunity energy of itself
Power.
The erythrocyte sedimentation rate (ESR) testing result of table 5
| <20mm/h | 20-50mm/h | 50-70mm/h | >70mm/h | |
| It is not used | 0 | 8 | 31 | 6 |
| Use 30 days | 18 | 30 | 6 | 1 |
| Use 60 days | 41 | 4 | 0 | 0 |
The normal range (NR) of erythrocyte sedimentation rate (ESR) should be 2-20mm/h.And by table 5, Ligusticum wallichii is not used in 52 patients
Erythrocyte sedimentation rate (ESR) is above normal value during essential oil.There is significant change using erythrocyte sedimentation rate (ESR) after Ligusticum wallichii essential oil, use 60 days
The erythrocyte sedimentation rate of 91% patient recovers normal afterwards, and the erythrocyte sedimentation rate of 9% patient is also tended to normally.
The C reactive protein testing result of table 6
| <10mg/L | 10-20mg/L | 20-40mg/L | >40mg/L | |
| It is not used | 0 | 12 | 21 | 12 |
| Use 30 days | 16 | 14 | 10 | 5 |
| Use 60 days | 41 | 4 | 0 | 0 |
The range of normal value of C reactive protein should in blood<10mg/L.It is anti-that 52 patients most start the C- without a people
Albumen is answered in range of normal value, obviously higher than normal value.And after using Ligusticum wallichii essential oil 30 days patient's C reactive protein
Content is substantially reduced, and the C reactive protein of 91% patient returns to normal value after using 60 days, only least a portion of
The C reactive protein of patient remains above normal value, but it is few to go beyond the scope, relative to it is unused when have obvious change.Table
The rheumatoid arthritis of 45 patients in face has obtained obvious improvement.
Human trial 3
The joint fluid of the 45 rheumatoid arthritis patients acted on embodiment 1 in human trial 1 is extracted simultaneously
Detection, extracts detection 3 times altogether.3 joint fluids extracted are respectively joint fluid before unused Ligusticum wallichii essential oil, using Ligusticum wallichii essential oil
Joint fluid after 30 days, uses the joint fluid after Ligusticum wallichii essential oil 60 days.The project of detection is the viscosity of joint fluid, cell number with
And albumen quality.Each detection project the results are shown in Table 7- tables 9.
The joint fluid viscosity of table 7
| Normally | Slight grumeleuse | Moderate grumeleuse | Severe grumeleuse | |
| It is not used | 0 | 3 | 21 | 21 |
| Use 30 days | 12 | 23 | 6 | 4 |
| Use 60 days | 41 | 4 | 0 | 0 |
Joint fluid viscosity detected using string test, and normal joint fluid viscosity is high, to will not form grumeleuse.
By table 7, the viscosity for the joint fluid that 45 patients of test most start is abnormal, and the Proportion of patients of severe grumeleuse is
47%.It is obviously improved being had using 30 days posterior joint liquid viscosityes of Ligusticum wallichii essential oil, uses the joint of 91% patient after 60 days
The viscosity of liquid recovers normal, further demonstrates that Ligusticum wallichii essential oil can effectively treat rheumatoid arthritis, also indicates that joint
Inflammation reduction between joint, synovitis is well controlled.
Cell number in the joint fluid of table 8
Normal cell number is 200-750/mm in joint fluid3, by table 8, use patient after Ligusticum wallichii essential oil
Cell quantity in joint fluid is substantially reduced, and normal model is returned to using the cell quantity of the joint fluid of 87% patient after 60 days
In enclosing, show that Ligusticum wallichii essential oil can effectively suppress and reduce the propagation of cell, the inflammation of synovial membrane between reduction joint and joint,
And then have good curative effect to rheumatoid arthritis.
Albumen quality in the joint fluid of table 9
| 11-22g/L | 22-30g/L | 30-35g/L | >35g/L | |
| It is not used | 0 | 5 | 15 | 25 |
| Use 30 days | 16 | 15 | 5 | 9 |
| Use 60 days | 43 | 2 | 0 | 0 |
Protein in natural joint liquid is 11-22g/L, and by table 9, the protein that 45 patients most start contains
Amount is abnormal, and after Ligusticum wallichii essential oil 30 days, the protein content for having 36% or so patient articular's liquid returns to normal value,
Though the content of the joint fluid protein of remaining patient is not recovered in range of normal value, there is substantially reduction, and use river
After rhizome of chuanxiong essential oil 60 days, the protein content of 96% patient returns to normal value, the protein content of only 4% or so patient
Normal value is remained above, but substantially close to normal value, protein content has been not present far above the patient of normal value.
Human trial 4
The experimental method and step of this human trial are consistent with the method and step of human trial 1, and difference is
200 patients are divided into 10 groups by the disease number of cases that this human trial is used for 200, what 10 groups of patients used respectively
The finish that Ligusticum wallichii essential oil finish is made for embodiment 2-11 Ligusticum wallichii essential oil.And 10 groups of return visit information is shown in Table 10-19 respectively.
The return visit information of the Ligusticum wallichii essential oil of the embodiment 2 of table 10
| It is invalid | Effectively | It is effective | Recovery from illness | |
| 30 days | 0 | 12 | 8 | 0 |
| 60 days | 0 | 0 | 6 | 14 |
By table 10, the Ligusticum wallichii essential oil of embodiment 2 is good for the therapeutic effect of rheumatoid arthritis, makes
After Ligusticum wallichii essential oil 60 days, 70% patient's recovery from illness, 30% patient feels effective.
The return visit information of the Ligusticum wallichii essential oil of the embodiment 3 of table 11
| It is invalid | Effectively | It is effective | Recovery from illness | |
| 30 days | 1 | 9 | 9 | 1 |
| 60 days | 0 | 1 | 3 | 16 |
By table 11, the Ligusticum wallichii essential oil of embodiment 3 is good for the therapeutic effect of rheumatoid arthritis, makes
After Ligusticum wallichii essential oil 60 days, 80% patient's recovery from illness, 15% patient feels effective.
The return visit information of the Ligusticum wallichii essential oil of the embodiment 4 of table 12
| It is invalid | Effectively | It is effective | Recovery from illness | |
| 30 days | 0 | 15 | 5 | 0 |
| 60 days | 0 | 2 | 5 | 13 |
By table 12, the Ligusticum wallichii essential oil of embodiment 4 is good for the therapeutic effect of rheumatoid arthritis, makes
After Ligusticum wallichii essential oil 60 days, 65% patient's recovery from illness, 25% patient feels effective.
The return visit information of the Ligusticum wallichii essential oil of the embodiment 5 of table 13
| It is invalid | Effectively | It is effective | Recovery from illness | |
| 30 days | 0 | 2 | 16 | 2 |
| 60 days | 0 | 0 | 1 | 19 |
By table 13, the Ligusticum wallichii essential oil of embodiment 5 is good for the therapeutic effect of rheumatoid arthritis, makes
After Ligusticum wallichii essential oil 60 days, 95% patient's recovery from illness, 5% patient feels effective.
The return visit information of the Ligusticum wallichii essential oil of the embodiment 6 of table 14
| It is invalid | Effectively | It is effective | Recovery from illness | |
| 30 days | 0 | 3 | 15 | 2 |
| 60 days | 0 | 1 | 3 | 16 |
By table 14, the Ligusticum wallichii essential oil of embodiment 6 is good for the therapeutic effect of rheumatoid arthritis, makes
After Ligusticum wallichii essential oil 60 days, 80% patient's recovery from illness, 15% patient feels effective.
The return visit information of the Ligusticum wallichii essential oil of the embodiment 7 of table 15
| It is invalid | Effectively | It is effective | Recovery from illness | |
| 30 days | 0 | 5 | 15 | 0 |
| 60 days | 0 | 0 | 3 | 17 |
By table 15, the Ligusticum wallichii essential oil of embodiment 7 is good for the therapeutic effect of rheumatoid arthritis, makes
After Ligusticum wallichii essential oil 60 days, 85% patient's recovery from illness, 15% patient feels effective.
The return visit information of the Ligusticum wallichii essential oil of the embodiment 8 of table 16
| It is invalid | Effectively | It is effective | Recovery from illness | |
| 30 days | 1 | 3 | 15 | 1 |
| 60 days | 0 | 1 | 3 | 16 |
By table 16, the Ligusticum wallichii essential oil of embodiment 8 is good for the therapeutic effect of rheumatoid arthritis, makes
After Ligusticum wallichii essential oil 60 days, 80% patient's recovery from illness, 15% patient feels effective.
The return visit information of the Ligusticum wallichii essential oil of the embodiment 9 of table 17
| It is invalid | Effectively | It is effective | Recovery from illness | |
| 30 days | 2 | 2 | 16 | 2 |
| 60 days | 1 | 2 | 8 | 9 |
By table 17, the Ligusticum wallichii essential oil of embodiment 9 is good for the therapeutic effect of rheumatoid arthritis, makes
After Ligusticum wallichii essential oil 60 days, 45% patient's recovery from illness, 40% patient feels effective.
The return visit information of the Ligusticum wallichii essential oil of the embodiment 10 of table 18
| It is invalid | Effectively | It is effective | Recovery from illness | |
| 30 days | 3 | 3 | 10 | 4 |
| 60 days | 0 | 4 | 6 | 10 |
By table 18, the Ligusticum wallichii essential oil of embodiment 10 is good for the therapeutic effect of rheumatoid arthritis,
After Ligusticum wallichii essential oil 60 days, 50% patient's recovery from illness, 30% patient feels effective.
The return visit information of the Ligusticum wallichii essential oil of the embodiment 11 of table 19
| It is invalid | Effectively | It is effective | Recovery from illness | |
| 30 days | 1 | 3 | 12 | 4 |
| 60 days | 0 | 1 | 8 | 11 |
By table 19, the Ligusticum wallichii essential oil of embodiment 11 is good for the therapeutic effect of rheumatoid arthritis,
After Ligusticum wallichii essential oil 60 days, 55% patient's recovery from illness, 40% patient feels effective.
The data obtained of analytical table 10- tables 19, it can be seen that the finish that embodiment 2 to the Ligusticum wallichii essential oil of embodiment 8 is made is to class
Rheumatic arthritis has good therapeutic effect, and the finish that the Ligusticum wallichii essential oil of embodiment 9- embodiments 11 is made can be wet to class
Property arthritis treated, but its therapeutic effect is slightly worse compared to embodiment 2- embodiments 8, illustrates to work as Jehol Ligusticum Rhizome in Ligusticum wallichii essential oil
Lactone mass percentage content is that 10%-70%, Senkyunolide A mass percentage content are 6%-15%, neocindilide
The therapeutic effect that it is applied to administer in the medicine of rheumatoid arthrosis when mass percentage content is 7%-15% is best.
In summary, the finish that Ligusticum wallichii essential oil provided in an embodiment of the present invention is made can be effectively improved the number of joint fluid
Measure, recover joint fluid viscosity, reduce the cell quantity in joint fluid, reduce joint fluid internal protein content.Reduce in blood
C reactive protein content in erythrocyte sedimentation rate (ESR), reduction blood in the content of rheumatoid factor, reduction blood, and then mitigate patient
Swelling, pain and the deformity of disease sites so that the joint of patient is no longer stiff, can be bent, and mitigate the negative of joint
Lotus.The Ligusticum wallichii essential oil of the embodiment of the present invention can effectively treat rheumatoid arthritis, such as synovitis, joint distending pain, pass
Section deformity.Ligusticum wallichii essential oil is prepared and easy to use, is easy to patient to use, toxic side effect is low.
In accordance with the above, because Ligusticum wallichii essential oil can be by with applied to the medicine for preparing treatment rheumatoid arthritis
In, therefore it can be applied to prepare in the health products of Saving cortilage.
Embodiments described above is a part of embodiment of the invention, rather than whole embodiments.The reality of the present invention
The detailed description for applying example is not intended to limit the scope of claimed invention, but is merely representative of the selected implementation of the present invention
Example.Based on the embodiment in the present invention, what those of ordinary skill in the art were obtained under the premise of creative work is not made
Every other embodiment, belongs to the scope of protection of the invention.
Claims (10)
1. application of the Ligusticum wallichii essential oil in treatment medicine for treating rheumatoid arthritis is prepared.
2. application according to claim 1, it is characterised in that the rheumatoid arthritis includes synovitis.
3. application according to claim 1, it is characterised in that the rheumatoid arthritis includes joint deformity.
4. application according to claim 1, it is characterised in that the rheumatoid arthritis includes painful swelling of joints.
5. the application according to claim 1-4 any one, it is characterised in that Ligustilide quality in the Ligusticum wallichii essential oil
Degree is 10%-70%.
6. application according to claim 5, it is characterised in that Senkyunolide A mass percent in the Ligusticum wallichii essential oil
Content is 6%-15%, and neocindilide mass percentage content is 7%-15%.
7. the application according to claim 1-4 any one, it is characterised in that the Ligusticum wallichii essential oil passes through following steps system
：
After Ligusticum wallichii is crushed according to mass ratio be 1:0.3-1.2 ratio is mixed with deionized water and soaked 7-24 hours；
The Ligusticum wallichii of moistening is heated using water vapour, mixed vapour is obtained, the mixed vapour is condensed and obtains profit
Mixture, carries out water-oil separating to the oil water mixture and obtains the Ligusticum wallichii essential oil.
8. application according to claim 7, it is characterised in that the particle diameter after the Ligusticum wallichii is crushed is 2-5mm.
9. the application according to claim 1-4 any one, it is characterised in that the Ligusticum wallichii essential oil passes through following steps system
：
After Ligusticum wallichii is crushed according to mass ratio be 1：2-15 ratio, which mixes with water and boils distillation, obtains mixed vapour；
Oil water mixture is obtained after condensing the mixed vapour, carrying out water-oil separating to the oil water mixture obtains the Ligusticum wallichii
Essential oil.
10. application of the Ligusticum wallichii essential oil in Saving cortilage health products are prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710258327.2A CN106974950A (en) | 2017-04-19 | 2017-04-19 | Application of the Ligusticum wallichii essential oil in treatment medicine for treating rheumatoid arthritis and Saving cortilage health products are prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710258327.2A CN106974950A (en) | 2017-04-19 | 2017-04-19 | Application of the Ligusticum wallichii essential oil in treatment medicine for treating rheumatoid arthritis and Saving cortilage health products are prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106974950A true CN106974950A (en) | 2017-07-25 |
Family
ID=59346001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710258327.2A Pending CN106974950A (en) | 2017-04-19 | 2017-04-19 | Application of the Ligusticum wallichii essential oil in treatment medicine for treating rheumatoid arthritis and Saving cortilage health products are prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106974950A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110624031A (en) * | 2019-09-26 | 2019-12-31 | 广西鹤兰墨生物科技有限公司 | Essential oil for lowering essence, nourishing meridian and health care |
| CN112386650A (en) * | 2020-12-15 | 2021-02-23 | 湖北中新药业有限公司 | Essential oil for treating rheumatic arthritis and rheumatoid arthritis and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103301407A (en) * | 2013-06-26 | 2013-09-18 | 陈黎光 | Ant wind dispelling essential oil liniment and preparation method thereof |
-
2017
- 2017-04-19 CN CN201710258327.2A patent/CN106974950A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103301407A (en) * | 2013-06-26 | 2013-09-18 | 陈黎光 | Ant wind dispelling essential oil liniment and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 大众养生网小编: "川芎精油的功效是什么？", 《HTTPS://WWW.CNDZYS.COM/XIAOBIAN/811931.HTML》 * |
| 无: "川芎油", 《WWW.HUANGYE88.COM/GYPXINXI/TIANJIAJI88223094.HTML》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110624031A (en) * | 2019-09-26 | 2019-12-31 | 广西鹤兰墨生物科技有限公司 | Essential oil for lowering essence, nourishing meridian and health care |
| CN112386650A (en) * | 2020-12-15 | 2021-02-23 | 湖北中新药业有限公司 | Essential oil for treating rheumatic arthritis and rheumatoid arthritis and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106309851A (en) | Traditional Chinese medicine tincture for treating neck-shoulder and waist-leg pain and preparation method of tincture | |
| CN109700901A (en) | A kind of Medical-use cold compress gel and its preparation method and application improving gout | |
| CN102058673A (en) | Chinese medicine composition for expelling wind and removing dampness and preparation method thereof | |
| CN1446569A (en) | Medicament for treating cervical spondylosis and preparation method thereof | |
| CN102106988B (en) | Chinese medicine preparation with effects on expelling wind, dispelling cold and dampness, promoting blood circulation, removing blood stasis, promoting qi circulation and relieving pain | |
| CN106974950A (en) | Application of the Ligusticum wallichii essential oil in treatment medicine for treating rheumatoid arthritis and Saving cortilage health products are prepared | |
| CN102727697B (en) | Traditional Chinese medicine composition for treating bone fracture, preparation method and mass detection method of traditional Chinese medicine composition | |
| CN105998435A (en) | Miao medicine preparation for treating osteoarticular diseases and preparation method and application thereof | |
| CN107468768A (en) | A kind of Qiang's drug composition and application thereof | |
| CN104208324A (en) | External medicine for treating gall caused by gout, rheumatism and rheumatoid arthritis and preparation method thereof | |
| CN104324317B (en) | A kind of Chinese medicine composition and medical usage for treating fibroid | |
| CN105832792A (en) | Blumea balsamifera essential oil for treatment of cervical spondylosis and lumbar diseases and preparation method thereof | |
| CN108310284A (en) | It is a kind of to be used to treat traditional Chinese medicine plaster of gout and preparation method thereof | |
| CN106890206A (en) | Application of the bighead atractylodes rhizome essential oil in treatment degenerative osteoarthropathy medicine is prepared | |
| CN107050081A (en) | Application of the asarum essential oil in treatment medicine for treating rheumatoid arthritis and Saving cortilage health products are prepared | |
| CN104800800A (en) | Traditional Chinese medicine composition for treating cervical spondylosis | |
| CN106974949A (en) | Application of the Ligusticum wallichii essential oil in treatment degenerative osteoarthropathy medicine is prepared | |
| CN105434799A (en) | Method for preparing traditional Chinese medicine composition for treating geriatric fracture | |
| CN104288664A (en) | Medicine curing hypochondriacal neurosis and preparation method for medicine | |
| CN104127856A (en) | Medicine used for treating knee osteoarthritis pain in anesthesia department and preparation method thereof | |
| CN103751703A (en) | Chinese herbal medicinal liquor used for treating arthromyodynia and preparation method thereof | |
| CN103585294A (en) | Plaster for treating osteoproliferation and preparation method of plaster | |
| CN104689176B (en) | A kind of Chinese medicine preparation for treating knee osteoarthritis and preparation method thereof | |
| CN102188629B (en) | External pain relieving tincture for muscular rheumatism | |
| CN106727752A (en) | Treat pharmaceutical composition of synovitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170725 |
|
| RJ01 | Rejection of invention patent application after publication |